- Home
- OCS vs OPT Comparison
OCS vs OPT Comparison
Compare OCS & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- OPT
- Stock Information
- Founded
- OCS 2003
- OPT 1984
- Country
- OCS Switzerland
- OPT Australia
- Employees
- OCS N/A
- OPT N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCS Health Care
- OPT Health Care
- Exchange
- OCS Nasdaq
- OPT Nasdaq
- Market Cap
- OCS 706.3M
- OPT 767.9M
- IPO Year
- OCS N/A
- OPT 2020
- Fundamental
- Price
- OCS $14.14
- OPT $3.24
- Analyst Decision
- OCS Strong Buy
- OPT Strong Buy
- Analyst Count
- OCS 5
- OPT 1
- Target Price
- OCS $29.20
- OPT $12.00
- AVG Volume (30 Days)
- OCS 73.4K
- OPT 39.0K
- Earning Date
- OCS 11-07-2024
- OPT 08-30-2024
- Dividend Yield
- OCS N/A
- OPT N/A
- EPS Growth
- OCS N/A
- OPT N/A
- EPS
- OCS N/A
- OPT N/A
- Revenue
- OCS $1,027,571.00
- OPT $261,859.00
- Revenue This Year
- OCS $4.38
- OPT N/A
- Revenue Next Year
- OCS $905.09
- OPT $46,864.64
- P/E Ratio
- OCS N/A
- OPT N/A
- Revenue Growth
- OCS N/A
- OPT N/A
- 52 Week Low
- OCS $9.60
- OPT $1.79
- 52 Week High
- OCS $18.00
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- OCS 37.01
- OPT 27.29
- Support Level
- OCS $16.44
- OPT $4.02
- Resistance Level
- OCS $18.00
- OPT $4.18
- Average True Range (ATR)
- OCS 0.68
- OPT 0.22
- MACD
- OCS -0.46
- OPT -0.13
- Stochastic Oscillator
- OCS 3.50
- OPT 6.85
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.